BMY vs PFE
Bristol Myers Squibb and Pfizer, both Healthcare
Pfizer is the larger company at $144B against $110B. On trailing earnings BMY is the cheaper of the two at a P/E of 13.0 against 37.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year BMY returned +34% against +23% for PFE. The RyuScore puts PFE ahead, 61 against 54 out of 100.
| Figure | BMY | PFE |
|---|---|---|
| Last close | $59.11 | $28.27 |
| Market cap | $110B | $144B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 13.0 | 37.2 |
| Dividend yield | 4.2% | 6.2% |
| 1-year return | +34% | +23% |
| 5-year return | +14% | -19% |
| RyuScoresector-relative, 1–10 | 54/100 | 61/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 33% of the disclosed total.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.